Physician profile
Kathryn Lynn Eckert
NPI 1710990924
$6,168.54
in general payments reported to CMS, 2019-2025
8 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 75% of Medical Biochemical Genetics providers received nationally (typical 2025 total: $149).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2021: $15.22 · 2022: $2,184 · 2023: $1,375 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,350 · Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,350.00 |
| Food and Beverage | $393.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $2,225.00 | 2025 | Javygtor |
| Biomarin Pharmaceutical INC. | $2,184.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $1,334.23 | 2019-2023 | Strensiq |
| Ucb, INC. | $143.24 | 2025 | |
| Genzyme Corporation | $124.99 | 2023 | |
| Kyowa Kirin, INC. | $124.99 | 2023 | |
| Insulet Corporation | $16.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Eckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.